Company Profile

Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment.

Leveraging decades of expertise in programmable DNA-binding proteins,the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generattion of genetic medicines designed to move beyonf disease management and toward lasting therapeutic impact.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC.

Cellectis ADS (Nasdaq)
Ticker: CLLS
↓$1.0300
-0.0300 (-2.8302%)
PREV. CLOSE
1.0600
VOLUME
6,020
HIGH
1.0850
CAPITALIZATION
74.256M
Last Update: 1 hours ago
Cellectis (Euronext Growth Paris)
Ticker: ALCLS
↓€0.9890
-0.0240 (-2.3692%)
PREV. CLOSE
1.0130
VOLUME
159,201
HIGH
1.0580
CAPITALIZATION
71.301M
Last Update: 6 hours ago